#Israel #financial results #Cancer Immunotherapy #Compugen #Holon

Compugen Ltd. Reports Third Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) has made headlines once again with its latest financial report for the third quarter of 2026. The Holon, Israel-based company, a pioneer in the field of cancer immunotherapy, has made significant progress in its clinical trials and has outlined its financial performance during this quarter.

Financial Overview

As of September 30, 2026, Compugen reported revenues of approximately $3.8 million, a notable increase from $1.9 million in the same period of the previous year. This revenue growth reflects portions of both the upfront payment and milestone achievements tied to the license agreement with Gilead. The research and development expenditures for this quarter were stable at around $5.8 million, suggesting a sustained commitment to advancing their research initiatives in immunotherapy.

The company also reported a net loss of approximately $5.8 million, which marks an improvement compared to the $7.0 million loss reported during the third quarter of 2025. This financial data showcases Compugen's effort to streamline operations while advancing its research agenda.

Clinical Trial Advancements

A major highlight is the completion of patient enrollment in Compugen's MAIA-ovarian trial, which assesses the efficacy of COM701, a promising anti-PVRIG antibody. This particular trial, aimed at patients suffering from relapsed platinum-sensitive ovarian cancer, has generated anticipation for results expected by the end of Q1 2027. The trial design is a double-blind, randomized study, which seeks to determine the effectiveness of COM701 as a maintenance therapy in a clinical space currently lacking approved treatment options.

In addition to COM701, Compugen is keenly observing the progress of its partner AstraZeneca's rilvegostomig, a bispecific antibody. High-level results from the ARTEMIDE-Biliary01 trial are set to be announced in the latter half of 2027. This trial evaluates the efficacy of rilvegostomig combined with conventional chemotherapy in biliary tract cancer patients.

Moreover, the company has announced the development of UnigenX™, an innovative extension of its AI-driven discovery platform aimed at identifying novel tumor-associated antigens. This initiative seeks to enhance targeted immune activation modalities, including T cell engagers, that could significantly improve treatment efficacy for patients with various types of cancer.

Cash Reserves

Compugen has reported approximately $117.5 million in cash and cash equivalents, anticipated to support corporate operations through 2029 without factoring additional cash inflows. This financial cushion is crucial as the company continues its commitment to research and clinical trials amid an evolving regulatory landscape.

Looking Ahead

The forthcoming year, 2027, is shaping up to be pivotal for Compugen, as they expect multiple data-related milestones from both the MAIA-ovarian trial and the ARTEMIDE-Biliary01 trial. Dr. Eran Ophir, the company's CEO, has expressed confidence in their strategic positioning and the potential of their drug development pipeline.

Compugen's innovative use of AI for drug target discovery underscores their commitment to advancing cancer immunotherapies. As they navigate through the next stages of clinical development, stakeholders remain optimistic about the potential transformative impact of their therapies on patient outcomes and overall cancer treatment paradigms.

Conclusion

In summary, Compugen Ltd. is on track with its financial and clinical objectives, showcasing growth in revenue while strategically progressing through its clinical trials. The anticipation of pivotal results in 2027 from various trials highlights the company's innovative approach in the ever-advancing field of cancer treatment. As they venture further into the realms of cancer immunotherapy, all eyes will be on how these developments unfold in the coming year.